Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4026
eHealth
EHTH
$21.5M
| $336K | ﹤0.01% |
72,950
+4,370
| +6% | +$19.3K |
2016 Q4
36 quarters
|
|
4027
TriSalus Life Sciences
TLSI
$266M
| $333K | ﹤0.01% |
47,699
+21,231
| +80% | +$119K |
2025 Q1
3 quarters
|
|
4028
BK Technologies
BKTI
$286M
| $332K | ﹤0.01% |
4,445
+150
| +3% | +$10.7K |
2024 Q4
4 quarters
|
|
4029
Park-Ohio Holdings
PKOH
$686M
| $331K | ﹤0.01% |
15,828
+1,640
| +12% | +$34.1K |
2023 Q2
10 quarters
|
|
4030
VTEX
VTEX
$603M
| $330K | ﹤0.01% |
87,792
+5,169
| +6% | +$21.2K |
2025 Q2
2 quarters
|
|
|
ACH
4031
Accendra Health
ACH
$38.9M
| $329K | ﹤0.01% |
117,603
+7,536
| +7% | +$26.9K |
2013 Q2
50 quarters
|
|
|
HERE
4032
Here Group Ltd
HERE
$92.5M
| $329K | ﹤0.01% |
64,368
-72,166
| -53% | -$445K |
2025 Q2
2 quarters
|
|
|
OLPX
4033
DELISTED
Olaplex Holdings
OLPX
| $328K | ﹤0.01% |
245,088
+21,292
| +10% | +$25.3K |
2022 Q1
15 quarters
|
|
|
SOLS
4034
PUT
Solstice Advanced Materials
SOLS
$9.17B
| $328K | ﹤0.01% |
+6,750
| New | +$318K |
2025 Q4
0 quarters
|
|
4035
Superior Group of Companies
SGC
$207M
| $328K | ﹤0.01% |
33,873
+1,632
| +5% | +$15.9K |
2023 Q3
9 quarters
|
|
4036
Hamilton Beach Brands
HBB
$511M
| $328K | ﹤0.01% |
19,930
+830
| +4% | +$12.6K |
2019 Q1
27 quarters
|
|
|
DAWN
4037
PUT
DELISTED
Day One Biopharmaceuticals
DAWN
| $326K | ﹤0.01% |
+35,000
| New | +$292K |
2025 Q4
0 quarters
|
|
|
KDK
4038
Kodiak AI
KDK
$329M
| $323K | ﹤0.01% |
29,597
-91,684
| -76% | -$734K |
2025 Q2
2 quarters
|
|
4039
Rocky Brands
RCKY
$350M
| $323K | ﹤0.01% |
11,006
+1,061
| +11% | +$31.2K |
2018 Q2
30 quarters
|
|
4040
Nano X Imaging
NNOX
$50M
| $323K | ﹤0.01% |
115,284
+24,822
| +27% | +$89.2K |
2022 Q1
15 quarters
|
|
4041
Gilat Satellite Networks
GILT
$773M
| $323K | ﹤0.01% |
+24,945
| New | +$320K |
2025 Q4
0 quarters
|
|
|
NREF
4042
NexPoint Real Estate Finance
NREF
$298M
| $322K | ﹤0.01% |
22,858
+951
| +4% | +$13.3K |
2022 Q2
14 quarters
|
|
4043
ProShares Short VIX Short-Term Futures ETF
SVXY
$261M
| $322K | ﹤0.01% |
5,810
| – | – |
2021 Q1
19 quarters
|
|
|
RJET
4044
Republic Airways Holdings
RJET
$826M
| $321K | ﹤0.01% |
+17,500
| New | +$364K |
2025 Q4
0 quarters
|
|
4045
CuriosityStream
CURI
$173M
| $321K | ﹤0.01% |
84,538
+29,971
| +55% | +$133K |
2024 Q4
4 quarters
|
|
4046
Spire Global
SPIR
$435M
| $321K | ﹤0.01% |
42,784
+626
| +1% | +$6.12K |
2024 Q2
6 quarters
|
|
4047
ProShares VIX Short-Term Futures ETF
VIXY
$216M
| $321K | ﹤0.01% |
12,500
| – | – |
2024 Q1
7 quarters
|
|
4048
Alico
ALCO
$284M
| $320K | ﹤0.01% |
8,795
+1,278
| +17% | +$44.5K |
2017 Q1
35 quarters
|
|
|
ARDT
4049
Ardent Health
ARDT
$1.46B
| $319K | ﹤0.01% |
36,137
+812
| +2% | +$9.39K |
2024 Q3
5 quarters
|
|
|
CD
4050
Chaince Digital Holdings
CD
$741M
| $318K | ﹤0.01% |
64,068
+19,020
| +42% | +$220K |
2025 Q2
2 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.